NAV

Mesenchymoangioblast-derived mesenchymal stem cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mesenchymoangioblast-derived mesenchymal stem cells
Accession Number
DB15739
Description

Mesenchymoangioblast (MCA)-derived mesenchymal stem cells (MSCs) originate from the mesoderm and are a common precursor for endothelial cells. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.

The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability. These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies.

Type
Biotech
Groups
Investigational
Synonyms
  • CYP-001
External IDs
  • Mesenchymoangioblast-derived mesenchymal stem cells

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

CYP-001 is a mesenchymal stem cell (MSC) product that is created from induced pluripotent stem cells. It was developed to treat steroid-resistant acute graft-versus-host disease (GvHD), and for preclinical models of asthma, limb ischemia, cytokine release syndrome, among others. As a regenerative medicine, CYP-001 is being used as a therapeutic to treat patients with COVID-19.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Koch JM, D'Souza SS, Schwahn DJ, Dixon I, Hacker TA: Mesenchymoangioblast-derived mesenchymal stromal cells inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy. 2016 Feb;18(2):219-28. doi: 10.1016/j.jcyt.2015.10.013. Epub 2015 Dec 28. [PubMed:26740280]
  2. Royce SG, Mao W, Lim R, Kelly K, Samuel CS: iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid. FASEB J. 2019 May;33(5):6402-6411. doi: 10.1096/fj.201802307R. Epub 2019 Feb 15. [PubMed:30768365]
  3. News Release [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2RecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 20:48 / Updated on August 13, 2020 07:02